Enanta CEO Jay Luly to Retire by February 1, 2027; Tara Kieffer Named COO
ENTA sits 17% above its 52-week low of $10.22.
Summary
Enanta's longtime CEO Jay Luly will retire by February 1, 2027, with the board searching for a successor and Tara Kieffer promoted to a new COO role. No successor has been named.
Key Events · Executive and Board Changes · ENTA
-
CEO to Retire by February 2027
Jay R. Luly, Ph.D., age 70, will retire as President and CEO by February 1, 2027 after 23 years with the company.
-
Advisory Role Through 2027
The company expects to enter an agreement for Luly to serve as a strategic advisor for the remainder of 2027 to support an orderly transition.
-
Successor Search Underway
The board has initiated a comprehensive search considering both internal and external candidates; no successor has been named.
-
New COO Appointed
Tara L. Kieffer, Ph.D., age 48, was appointed to the newly created Chief Operating Officer role; she joined Enanta in 2020 and most recently served as Chief Product Strategy Officer.
Analysis · ENTA · Life Sciences
The 23-year CEO is stepping down at a pivotal moment: Enanta is burning roughly $19.5M a quarter against $211.5M in cash and leaning on a $75M at-the-market facility to fund its RSV and immunology pipeline. Luly stays on as a strategic advisor through 2027, and the board is running a full internal-and-external search, so no successor has been named yet — that gap is the real uncertainty. Meanwhile, the simultaneous promotion of Tara Kieffer to a newly created COO role puts an operational leader in place and gives the board an internal option, but investors won't know the direction of the next CEO until the search concludes.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTA was trading at $11.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $354.7M. The 52-week trading range was $10.22 to $17.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.